Retroperitoneal fibrosis.
Summary
Online ahead of print. Review Article Retroperitoneal fibrosis. Vaglio A(1), Peyronel F(2), Bajema IM(3), Pegoraro F(4). Author information: (1)Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy; Nephrology and Dialysis Unit, Meyer Children's Hospital IRCCS, Florence, Italy. Electronic address: augusto.vaglio@unifi.it. (2)Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. (3)Department of
Content
# Online ahead of print.
*Review Article*
Retroperitoneal fibrosis.
Vaglio A(1), Peyronel F(2), Bajema IM(3), Pegoraro F(4).
Author information:
(1)Department of Biomedical, Experimental and Clinical Sciences "Mario Serio",
University of Florence, Florence, Italy; Nephrology and Dialysis Unit, Meyer
Children's Hospital IRCCS, Florence, Italy. Electronic address:
augusto.vaglio@unifi.it.
(2)Department of Experimental and Clinical Medicine, University of Florence,
Florence, Italy.
(3)Department of Pathology and Medical Biology, University of Groningen,
University Medical Center Groningen, Groningen, Netherlands.
(4)Department of Experimental and Clinical Medicine, University of Florence,
Florence, Italy; Onco-hematology Unit, Meyer Children's Hospital IRCCS,
Florence, Italy.
Retroperitoneal fibrosis is a rare immune-mediated disease characterised by a
periaortoiliac fibro-inflammatory tissue that often encases neighbouring
structures (eg, ureters). Idiopathic retroperitoneal fibrosis can be isolated or
part of IgG4-related disease, whereas secondary forms recognise different
aetiologies, such as histiocytosis, malignancies, and infections. Idiopathic
retroperitoneal fibrosis has a multifactorial origin, with genetic,
environmental, and lifestyle factors being main contributors. The
immunopathogenesis of the disease involves B-lymphocyte and T-lymphocyte
crosstalk, macrophage and fibrocyte chemotaxis, and recruitment of eosinophils
and mast cells. Idiopathic retroperitoneal fibrosis can cause severe
complications, such as acute or chronic kidney injury, caval occlusion, and deep
vein thrombosis. Although interventional or surgical procedures can be necessary
to manage these complications, medical therapy remains the cornerstone of
treatment. Glucocorticoids are effective, and B-cell-targeting therapies are
increasingly used. However, relapses are frequent after treatment
discontinuation. In this Seminar, we provide a contemporary overview of
retroperitoneal fibrosis focusing on pathophysiology, differential diagnosis,
and management.
---
DOI: 10.1016/S0140-6736(26)00037-1